Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    National Security
    Science & Regulatory
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    .
    Human Health
    Startups
    .
    Non-R&D Companies
    Member Savings
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Investor Forum
    BIO Asia-Taiwan

    July 15-19, 2026
    Taipei, Taiwan

    BIO Patient & Health Advocacy Summit
    BIO Patient Advocacy Changemakers Event

    October 22-23, 2026
    Washington, D.C

    BIO Asia-Taiwan
    BIO Europe

    November 9-11, 2026
    Cologne, Germany

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyNational SecurityScience & RegulatoryAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3233 results found
Expand All
Apply All
3233 results found

BIO Comments on FDA’s Public Workshop on Implementation of the Integrated Assessment of Marketing Applications and Integrated Review Documentation
Share
Human Health  •  Letters, Testimony & Comments  •  December 23, 2020
On Wednesday, December 23rd, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s October 2020 public workshop titled, “New Drugs Regulatory Program Modernization: Implementation of the Integrated Assessment of Marketing Applications and Integrated Review Documentation.” In its comments, BIO stated that the FDA’s new integrated review documentation is much improved from the older template as it is easier to navigate and provides greater clarity and transparency on key information considered in the review process. However, BIO requests that the Agency ensures any relevant information is not removed or omitted as the new documentation is implemented, and that this information remain publicly available. BIO also proposed additional strategies for the Agency to utilize in increasing transparency in the regulatory approval process. Lastly, given current technology, BIO encouraged the FDA to consider providing the information included in the integrated review in an electronic format that can easily be searched across products.  
Read More

What you need to know about vaccine allocation
Share
Bio.News  •  December 23, 2020
Don’t put on your “out of office” message quite yet, because we have a few things you need to know about COVID-19 vaccine allocation. Plus, we close the year with a look at some of our newest members and why they decided to join. (863 words, 4 minutes, 18 seconds)    Good Day BIO is taking a holiday break—and we hope you do, too. We will resume normal publication on Monday, January 4, 2021, though we will pop in your inbox if there’s major news. Happy Holidays!
Read More

A step towards modernized animal biotech regulation
Share
Bio.News  •  December 22, 2020
So much for a slow news week. Yesterday, USDA proposed a rulemaking regarding transferring authority over agricultural animal biotech from FDA to USDA—a welcome step towards a modernized animal biotech regulatory system (and a policy priority for BIO). We also catch you up on the COVID-19 vaccine news. (737 words, 3 minutes, 41 seconds)
Read More

Modernizing Oversight of Animal Biotechnology Will Help Tackle Climate Change and Nutrition Challenges
Share
Press Release  •  December 21, 2020
The Biotechnology Innovation Organization (BIO) appreciates the U.S. Department of Agriculture’s (USDA) longstanding commitment to food and agricultural innovation and looks forward to reviewing the Advanced Notice of Proposed Rulemaking (ANPR) aimed at restructuring the U.S. regulatory system for animal biotechnology. The following statement may be attributed to Dana O'Brien, BIO Executive Vice President for Food & Agriculture: “It’s essential for the U.S. Government’s oversight of animal biotechnology to be science-based and focused on the health and safety of animals, consumers, and the environment. “This system must also provide researchers and technology developers with clarity and predictability to foster scientific progress and restore investment in American innovation. Many of these discoveries are made possible by small and mid-sized companies based in rural communities, which provide jobs and help to boost our bioeconomy. “A modern U.S. regulatory system will pave the way for breakthroughs that can help prevent and respond to zoonotic diseases such as COVID-19, improve animal well-being, address hunger and nutrition, make our farming and food systems more sustainable, protect our environment, and bolster our resilience to climate change. “The new Food and Agriculture Climate Alliance, representing a broad spectrum of stakeholders in the agriculture, environmental, and food community, recognizes that improved animal genetics can help livestock adapt to a changing climate and contribute to reduced greenhouse gas emissions. “We thank USDA for its leadership and look forward to working with the FDA and USDA and the incoming Biden Administration to ensure appropriate safety measures remain in place, and that consumers are confident in the rigor of the system. BIO remains committed to improving public access to information about new agricultural technologies, and we are working with our stakeholder partners to drive transparency measures that…
Read More

The frightening campaign to keep us unvaccinated
Share
Bio.News  •  December 21, 2020
Congratulations to BIO member Moderna on the emergency use authorization of your COVID-19 vaccine, the second vaccine to be authorized for use in the United States! These vaccines are safe and effective—but some Americans remain hesitant to get them. We discuss why and how we can tackle it, as well as take a look at what’s needed to grow the bioeconomy moving forward. (920 words, 4 minutes, 36 seconds)
Read More

The payroll R&D credit, five years on
Share
Bio.News  •  December 18, 2020
Yesterday, an FDA independent advisory panel voted to endorse Moderna’s COVID-19 vaccine, clearing the way for emergency use authorization as soon as today. Meanwhile, we’re taking a look at the payroll R&D tax credit, Washington State’s plans for a low-carbon fuel standard, and whether the federal government will shut down tonight. (767 words, 3 minutes, 50 seconds)
Read More

Survey on Payroll R&D Credit
Share
BIO will soon be launching a survey on the Payroll R&D Credit. This Credit, which was introduced in the PATH Act in 2015, allowed pre-revenue innovators to take a portion of their R&D credit against their payroll tax obligation. The survey will help us assess the impact and usage of the Credit and will support our advocacy in the new Congress. To sign up to receive the survey when it is launched, please fill out the below form.
Read More

Behind CMS' new data on health care spending
Share
Bio.News  •  December 17, 2020
The FDA Vaccines and Related Biological Products Advisory Committee meets today to discuss emergency use authorization of the Moderna COVID-19 vaccine. In other news, we look at new data on health care spending and the future of gene editing. (916 words, 4 minutes, 34 seconds)
Read More

“This is the time for us to talk about the science”
Share
Bio.News  •  December 16, 2020
COVID-19 vaccines are here—but how do we ensure people will get them when it’s their turn? BIO’s Dr. Michelle McMurry-Heath discussed this on CNN. Meanwhile, 2021 is shaping up to be a critical year in the war on climate change, so we take a look at the many ways gene editing can contribute. (834 words, 4 minutes, 10 seconds)
Read More

COVID-19 vaccines are here—but future innovation is at risk
Share
Bio.News  •  December 15, 2020
The emergency use authorization of a COVID-19 vaccine less than one year after the virus was identified is an amazing feat—but attempts to weaken IP protections could undermine this kind of innovation in the future. We explain why, plus look at how one company is successfully marketing its GM apples to consumers. (871 words, 4 minutes, 20 seconds)
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 213
  • 214
  • 215
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO Investment and Growth Summit
BIO Partnering™ for Oncology
BIO International Convention
BIO Partnering™ at JPM Week
BIO Patient Advocacy Changemakers Events
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2026 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO